Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase NA 6Phase 4 6Phase 3 4Phase 1 3

Status

Completed 4

Sponsor Class

INDUSTRY 8OTHER 4NETWORK 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Tumor-Agnostic 1Sarcoma 1Gynecologic 1Genitourinary 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Diarrhea 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 294Radiotherapy 230Fluorouracil 201Cyclophosphamide 191Capecitabine 183Docetaxel 167Gemcitabine 165Oxaliplatin 162Carboplatin 161Paclitaxel 152Leucovorin 122Drug Therapy 119Dexamethasone 119Doxorubicin 112Etoposide 99Bevacizumab 91Cytarabine 87Vincristine 83Irinotecan 81Rituximab 77Epirubicin 71Prednisone 65Radiosurgery 63Methotrexate 62Surgical Procedures, Operative 61Radiation 60Radiotherapy, Intensity-Modulated 57Neoadjuvant Therapy 53Lenalidomide 52Letrozole 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × OTHER × Octreotide × Clear all
NCT02457156 2025-03-13

PANasta

University of Liverpool

Phase 3 Completed
295 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00182754 2017-04-11

Octreotide in Treating Patients With Cancer-Related Malignant Ascites

Alliance for Clinical Trials in Oncology

Phase 3 Completed
33 enrolled 9 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT00033605 2016-07-13

Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

Alliance for Clinical Trials in Oncology

Phase 3 Completed
130 enrolled
GastrointestinalGenitourinaryGynecologicSarcoma

Uterine Cervical Neoplasms, Diarrhea, Fallopian Tube Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vaginal Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT00386984 2006-10-12

Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma

University Hospital Freiburg

Phase 3 Completed
108 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡